Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $22.29 Average Price Target from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $22.29.

Several research firms have issued reports on ZVRA. Guggenheim boosted their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, March 13th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday, March 13th. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Finally, Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director John B. Bode bought 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the transaction, the director now owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 85,773 shares of company stock valued at $674,176 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Zevra Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in shares of Zevra Therapeutics during the 4th quarter valued at approximately $53,000. GAMMA Investing LLC lifted its position in Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after purchasing an additional 8,020 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Zevra Therapeutics in the 4th quarter worth $94,000. XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics in the 3rd quarter worth about $94,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics during the 3rd quarter valued at about $95,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $6.59 on Friday. The firm’s 50 day moving average price is $7.76 and its 200-day moving average price is $8.17. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $356.62 million, a PE ratio of -3.35 and a beta of 1.94. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. Equities research analysts expect that Zevra Therapeutics will post -1.95 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.